Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
Avacta Group plc, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial
GSK’s shares rose at the opening of trading after the company reported that its Q1 revenue and profits had exceeded expectations, driven by the success of its Shingrix shingles vaccine.
SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).
Activation of First Clinical Trial Site in the U.S
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its ongoing
Transformational year with record EBITDA underlining strong operational delivery
A period of continued significant progress
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a liquid biopsy company, announced that it achieved a significant milestone in 2022, with clearance from the US Food & Drug Administration (FDA) and
Avacta Presents AVA3996 Pre-clinical Data at the American Association for Cancer Research Meeting
If you were to walk into the imaging department of any NHS hospital, what would you see? A room filled with patients waiting for X-rays, ultrasounds, and other diagnostic procedures.